TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2025. Filed Feb 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | |
|---|---|
| By: | /s/ Richard D. Francis |
| Name: | Richard D. Francis |
| Title: | President and Chief Executive Officer |
| Date: | February 3, 2026 |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENT, that each of the undersigned directors and/or officers of Teva Pharmaceutical Industries Limited, a corporation organized under the laws of Israel, hereby constitutes and appoints Richard D. Francis, Eli Kalif, David R. McAvoy and Amir Weiss, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign, execute and deliver with the U.S. Securities and Exchange Commission any and all amendments to this Annual Report on Form 10-K, with all exhibits thereto, and other documents in connection therewith, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date | |
| By: | /s/ Dr. Sol J. Barer Dr. Sol J. Barer | Chairman of the Board of Directors | February 3, 2026 |
|---|---|---|---|
| By: | /s/ Richard D. Francis Richard D. Francis | President and Chief Executive Officer and Director | February 3, 2026 |
| By: | /s/ Eli Kalif Eli Kalif | Executive Vice President, Chief Financial Officer (Principal Financial Officer) | February 3, 2026 |
| By: | /s/ Amir Weiss Amir Weiss | Senior Vice President, Chief Accounting Officer (Principal Accounting Officer) | February 3, 2026 |
| By: | /s/ Rosemary A. Crane Rosemary A. Crane | Director | February 3, 2026 |
| By: | /s/ Amir Elstein Amir Elstein | Director | February 3, 2026 |
| Name | Title | Date | |
| By: | /s/ Chen Lichtenstein Chen Lichtenstein | Director | February 3, 2026 |
|---|---|---|---|
| By: | /s/ Gerald M. Lieberman Gerald M. Lieberman | Director | February 3, 2026 |
| By: | /s/ Roberto A. Mignone Roberto A. Mignone | Director | February 3, 2026 |
| By: | /s/ Dr. Perry D. Nisen Dr. Perry D. Nisen | Director | February 3, 2026 |
| By: | /s/ Prof. Ronit Satchi-Fainaro Prof. Ronit Satchi-Fainaro | Director | February 3, 2026 |
| By: | /s/ Prof. Varda Shalev Prof. Varda Shalev | Director | February 3, 2026 |
| By: | /s/ Janet S. Vergis Janet S. Vergis | Director | February 3, 2026 |
| By: | /s/ Dr. Tal Zaks Dr. Tal Zaks | Director | February 3, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.